EP Patent

EP3528791A1 — Dispersible compositions

Assigned to Janssen Sciences Ireland ULC · Expires 2019-08-28 · 7y expired

What this patent protects

The present invention is concerned with dispersible compositions comprising rilpivirine or a pharmaceutically acceptable acid addition salt thereof as an active ingredient. Such compositions are useful in the treatment of HIV infection and their dispersibility properties lend the…

USPTO Abstract

The present invention is concerned with dispersible compositions comprising rilpivirine or a pharmaceutically acceptable acid addition salt thereof as an active ingredient. Such compositions are useful in the treatment of HIV infection and their dispersibility properties lend themselves to be useful in particular amongst the pediatric or geriatric population.

Drugs covered by this patent

Patent Metadata

Patent number
EP3528791A1
Jurisdiction
EP
Classification
Expires
2019-08-28
Drug substance claim
No
Drug product claim
No
Assignee
Janssen Sciences Ireland ULC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.